Biocon Group chairperson Kiran Mazumdar-Shaw predicts FY26 as a growth year, fueled by biosimilars, generics, and research ...

Kiran Mazumdar-Shaw discusses the impact of US drug price reduction efforts on Indian pharma, Biocon's US expansion, strong ...

Kiran Mazumdar-Shaw suggestion was met with a flurry of responses, with many users pushing back against the idea.

the board was of the opinion that we should look at other strategic options which also be includes evaluating a merger," Kiran Mazumdar-Shaw, chairperson, Biocon Group, told investors in an ...

US President Donald Trump’s move to slash prescription drug prices by tying them to rates in countries such as the UK and ...

said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon, adding that one needs to wait for more details on the order to ascertain the full impact. Speaking to CNBC TV18 on May 13 ...

Biocon founder and global business leader Kiran Mazumdar Shaw has set an ambitious vision for India’s media and entertainment sector, calling for its expansion from a $20 billion GDP contributor today ...

Touching on India’s demographic advantage, Shaw highlighted the country’s youth and digital infrastructure as key assets.

The Chairperson of Biocon Group said that generics and biosimilars are clearly part of the Affordable Care Act, but they are not the target of President Trump's current efforts.

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ...

Trump’s EO on MFN prescription drugs to strengthen adoption of generics & biosimilars: Nandita Vijayasimha, Bengaluru Thursday, May 15, 2025, 08:00 Hrs [IST] US President Donald ...

Shaw highlighted the importance of elevating this sector in line with Prime Minister Narendra Modi’s vision of a globally ...